1-20 of 115
selinexor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165-3174.

Journal: Blood
Blood (2020) 136 (2): 259.
https://doi.org/10.1182/blood.2020007231
Published: 2020
Journal Articles

Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129(24):3175-3183.

Journal: Blood
Blood (2020) 136 (2): 259.
https://doi.org/10.1182/blood.2020007232
Published: 2020
Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB
Journal: Blood
Blood (2019) 134 (Supplement_1): 574.
https://doi.org/10.1182/blood-2019-130977
Published: 2019
Journal Articles

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

Ajay K Nooka, MDMPH, Andrew J. Yee, MD, Carol Ann Huff, MD, Dan T. Vogl, MD, Maria Gavriatopoulou, MD, Ajai Chari, MD, Philippe Moreau, MD, David Dingli, MD PhD, Craig E. Cole, MD, Sagar Lonial, Meletios A. Dimopoulos, MD, Joshua R Richter, MD, Ravi Vij, MBBS, Sascha A Tuchman, MD, Marc S Raab, MD PhD, Noa Biran, MD, David S. Siegel, Paul G. Richardson, MD, Jianjun Liu, Anita Joshi, PhD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1872.
https://doi.org/10.1182/blood-2019-122908
Published: 2019
Journal Articles

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy S. Pardee, MD PhD, Kris C Wood, PhD, Kevin H Lin, BS, Justine Rutter, PhD, Mariaelena Pierobon, MD, Emanuel Petricoin, PhD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L Powell, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1388.
https://doi.org/10.1182/blood-2019-129413
Published: 2019
Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1885.
https://doi.org/10.1182/blood-2019-125383
Published: 2019
Journal Articles

Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Ajai Chari, MD, Dan T. Vogl, MD, Sundar Jagannath, MD, Jagoda K. Jasielec, MD, Andrew DeCastro, PhD, TJ Unger, PhD, Jatin Shah, MD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1854.
https://doi.org/10.1182/blood-2019-128887
Published: 2019
Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2997.
https://doi.org/10.1182/blood-2019-124136
Published: 2019
Journal Articles

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, PhD, Sherry Bhalla, Adolfo Aleman, Anna Huo-Chang Mei, MS, Violetta Leshchenko, PhD, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepu Madduri, MD, Joshua R Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3101.
https://doi.org/10.1182/blood-2019-130753
Published: 2019
Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3314.
https://doi.org/10.1182/blood-2019-131321
Published: 2019
Journal Articles

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Darrell J White, MD, Suzanne Lentzsch, MD PhD, Cristina Gasparetto, MD, Nizar Bahlis, MD, Christine I Chen, MD, Brea C. Lipe, MD, Gary J. Schiller, MD, Sascha A Tuchman, MD, Heather J. Sutherland, MD PhD, Rami Kotb, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Christopher P Venner, MD, Natalie Scott Callander, MD, William I. Bensinger, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Muhamed Baljevic, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3165.
https://doi.org/10.1182/blood-2019-124370
Published: 2019
Journal Articles

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment

Ajeet Gajra, MD FACP, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Bruce Feinberg, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 5822.
https://doi.org/10.1182/blood-2019-129502
Published: 2019
Journal Articles

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Ian Gould, PhD, Jan Bassali, PharmD, Jyotsna Mehta, Jatin Shah, MD, Dee Dee Mladsi, BA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5824.
https://doi.org/10.1182/blood-2019-125997
Published: 2019
Journal Articles

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Christine I Chen, MD, Nizar Bahlis, MD, Cristina Gasparetto, MD, Sascha A Tuchman, MD, Brea C. Lipe, MD, Muhamed Baljevic, MD, Rami Kotb, MD, Heather J. Sutherland, MD PhD, William I. Bensinger, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Christopher P Venner, MD, Gary J. Schiller, MD, Suzanne Lentzsch, MD PhD, Natalie Scott Callander, MD, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Darrell J White, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 141.
https://doi.org/10.1182/blood-2019-122907
Published: 2019
Journal Articles

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Deborah M. Stephens, DO, Ying Huang, MS, MA, Akwasi Agyeman, Amy S. Ruppert, MAS, PhD, Boyu Hu, MD, Natalie Turner, APRN, Renee Vadeboncoeur, MSN, APRN, Kerry A Rogers, MD, Seema A. Bhat, MD, Basem M. William, MRCP,MD, Samantha Jaglowski, MDMPH, Hank Lockman, Martha Glenn, MD, Rosa Lapalombella, PhD, John C. Byrd, MD, Jennifer Woyach, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4310.
https://doi.org/10.1182/blood-2019-124544
Published: 2019
Journal Articles

Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

Federica Cavallo, MD PhD, George A Follows, MD PhD, Andre Goy, MD, Joost Vermaat, MD PhD, Rene-Olivier Casasnovas, MD, Orly Lavee, MD, Marie Maerevoet, MD, Josée M Zijlstra, MD PhD, Sameer Bakhshi, MD, Reda Bouabdallah, Sylvain Choquet, MD, Ronit Gurion, MD, Brian T. Hill, MD, Ulrich Jaeger, MD, Juan-Manuel Sancho, MD PhD, Michael W. Schuster, MD, Catherine Thieblemont, MD PhD, Fatima De la Cruz, MD, Miklos Egyed, MD PhD, Sourav Mishra, Fritz Offner, MD, Theodoros P. Vassilakopoulos, MD PhD, Krzysztof Warzocha, Daniel McCarthy, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita Joshi, PhD, Jatin Shah, MD, Eric Van Den Neste, MD, Miguel A Canales, MD PhD, Nagesh Kalakonda, FRCPath PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5333.
https://doi.org/10.1182/blood-2019-122900
Published: 2019
Journal Articles

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Sarah R Brown, PhD MSc, BSc, Andrew Hall, Jessica Kendall, BSc, MSc, Emma Ingleson, Louise Flanagan, PhD, Holger W Auner, MD PhD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Mamta Garg, MD FRCP, FRCPath, Martin F. Kaiser
Journal: Blood
Blood (2019) 134 (Supplement_1): 5552.
https://doi.org/10.1182/blood-2019-123672
Published: 2019
Journal Articles

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Kensuke Kojima, MD PhD, Rafael Heinz Montoya, Naval G. Daver, MD, Arnaud Lesegretain, Sharon Shacham, PhD MBA, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2556.
https://doi.org/10.1182/blood-2019-126950
Published: 2019
Journal Articles

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

Luciano J. Costa, MD PhD, Parameswaran Hari, MBBS, MD, Shaji K. Kumar, MD, Shijie Tang, Ujjawal H Gandhi, PhDMBBS, Jatin J. Shah, MD, Sundar Jagannath, MD, Ajai Chari, MD, Arjun Lakshman, MBBS, Sharon Shacham, PhD MBA, Xiwen Ma, David S. Siegel, Noa Biran, MD, Sagar Lonial, Paul G. Richardson, MD, Michael G. Kauffman, MD PhD, Ehsan Malek, MD, Kelly N. Godby, MD, Mark A. Fiala, BS, Saurabh Chhabra, MD, Saad Z. Usmani, MD, Natalie Scott Callander, MD, Yubin Kang, MD, Amarendra K. Neppalli, MD, Elvira Umyarova, MD, Robert F. Cornell, MD MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 3125.
https://doi.org/10.1182/blood-2019-124991
Published: 2019
Journal Articles

A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)

Cristina Gasparetto, MD, Gary J. Schiller, MD, Natalie Scott Callander, MD, Suzanne Lentzsch, MD PhD, Sascha A Tuchman, MD, Nizar Bahlis, MD, Darrell J White, MD, Christine I Chen, MD, Heather J. Sutherland, MD PhD, Muhamed Baljevic, MD, Rami Kotb, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Christopher P Venner, MD, William I. Bensinger, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Brea C. Lipe, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3157.
https://doi.org/10.1182/blood-2019-122902
Published: 2019